It has also found more advanced stages, larger tumor sizes, greater lymph node metastases, higher tall-cell PTCs, lower follicular PTC proportions, more BRAF mutations, and fewer RAS mutations in high-immunity group [68], suggesting that thyroid cancer harbors an abundance of immune cells in TME that affects tumor biology. Here, BRAF is linked to thyroid gland carcinoma.